Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
You may also be interested in...
India's Glenmark gets US Complete Response Letter for Ryaltris but emphasizes the FDA hasn’t faulted the clinical data for the product, and that the action won’t impact recent alliances for the rhinitis asset.
Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.
Glenmark has snagged a top name in oncology from Gilead to lead its spin-out innovation business.